These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 30690761)

  • 1. Pharmacometrics and systems pharmacology for metabolic bone diseases.
    Riggs MM; Cremers S
    Br J Clin Pharmacol; 2019 Jun; 85(6):1136-1146. PubMed ID: 30690761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory aspects of the development of drugs for metabolic bone diseases - FDA and EMA perspective.
    Kehoe T; Blind E; Janssen H
    Br J Clin Pharmacol; 2019 Jun; 85(6):1208-1212. PubMed ID: 30335197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology of bisphosphonates.
    Cremers S; Drake MT; Ebetino FH; Bilezikian JP; Russell RGG
    Br J Clin Pharmacol; 2019 Jun; 85(6):1052-1062. PubMed ID: 30650219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perspective on model-informed drug development.
    Lesko LJ
    CPT Pharmacometrics Syst Pharmacol; 2021 Oct; 10(10):1127-1129. PubMed ID: 34404115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel targets for the prevention of osteoporosis - lessons learned from studies of metabolic bone disorders.
    Henriksen K; Thudium CS; Christiansen C; Karsdal MA
    Expert Opin Ther Targets; 2015; 19(11):1575-84. PubMed ID: 25960169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamics of Bone Cell Interactions and Differential Responses to PTH and Antibody-Based Therapies.
    Lemaire V; Cox DR
    Bull Math Biol; 2019 Sep; 81(9):3575-3622. PubMed ID: 30460589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on pharmacologically-relevant vitamin D analogues.
    Jones G; Kaufmann M
    Br J Clin Pharmacol; 2019 Jun; 85(6):1095-1102. PubMed ID: 30308088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Side effects of drugs for osteoporosis and metastatic bone disease.
    Skjødt MK; Frost M; Abrahamsen B
    Br J Clin Pharmacol; 2019 Jun; 85(6):1063-1071. PubMed ID: 30192026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Secondary osteoporosis UPDATE. Drugs under development for metabolic bone disease].
    Endo I; Matsumoto T
    Clin Calcium; 2010 May; 20(5):700-8. PubMed ID: 20445281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM; Iranikhah MM; Wilborn TW
    Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonates in the treatment of metabolic bone diseases.
    Arantes HP; Silva AG; Lazaretti-Castro M
    Arq Bras Endocrinol Metabol; 2010 Mar; 54(2):206-12. PubMed ID: 20485910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Bone remodeling: new therapeutic approaches].
    Ferrari S
    Rev Med Suisse; 2009 Jun; 5(207):1325-8. PubMed ID: 19626933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using early biomarker data to predict long-term bone mineral density: application of semi-mechanistic bone cycle model on denosumab data.
    Zheng J; van Schaick E; Wu LS; Jacqmin P; Perez Ruixo JJ
    J Pharmacokinet Pharmacodyn; 2015 Aug; 42(4):333-47. PubMed ID: 26123919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Where Do PBPK Models Stand in Pharmacometrics and Systems Pharmacology?
    Jamei M
    CPT Pharmacometrics Syst Pharmacol; 2020 Feb; 9(2):75-76. PubMed ID: 31905421
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacotherapies to manage bone loss-associated diseases: a quest for the perfect benefit-to-risk ratio.
    Valverde P
    Curr Med Chem; 2008; 15(3):284-304. PubMed ID: 18288984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone biology, signaling pathways, and therapeutic targets for osteoporosis.
    Iñiguez-Ariza NM; Clarke BL
    Maturitas; 2015 Oct; 82(2):245-55. PubMed ID: 26255682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteoanabolic and dual action drugs.
    Tabacco G; Bilezikian JP
    Br J Clin Pharmacol; 2019 Jun; 85(6):1084-1094. PubMed ID: 30218587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drugs for the treatment of metabolic bone diseases.
    Drake MT; Cremers S; Russell RG; Bilezikian JP
    Br J Clin Pharmacol; 2019 Jun; 85(6):1049-1051. PubMed ID: 30950086
    [No Abstract]   [Full Text] [Related]  

  • 19. The vitamin D analogue 2MD increases bone turnover but not BMD in postmenopausal women with osteopenia: results of a 1-year phase 2 double-blind, placebo-controlled, randomized clinical trial.
    DeLuca HF; Bedale W; Binkley N; Gallagher JC; Bolognese M; Peacock M; Aloia J; Clagett-Dame M; Plum L
    J Bone Miner Res; 2011 Mar; 26(3):538-45. PubMed ID: 20890933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonates and metabolic bone disease in the ICU.
    Hollander JM; Mechanick JI
    Curr Opin Clin Nutr Metab Care; 2009 Mar; 12(2):190-5. PubMed ID: 19209471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.